Keyphrases
Acquired Thrombotic Thrombocytopenic Purpura
16%
Adult Patients
19%
Adverse Pregnancy Outcomes
26%
Aggressive non-Hodgkin Lymphoma
28%
Anticoagulants
15%
Antiphospholipid Antibodies
26%
BCR-ABL Transcript
43%
Bleeding
21%
Bleeding Risk
16%
Bone Marrow
18%
Bone Marrow Aspirate
26%
Breast Cancer
17%
Chemotherapy
30%
Chronic Lymphocytic Leukemia
16%
Clinical Practice Guidelines
26%
Clinical Presentation
28%
Coagulation Factors
17%
COVID-19
25%
Direct Oral Anticoagulants
21%
Essential Thrombocythemia
52%
Fresh Frozen Plasma
21%
Glycoprotein
22%
High Risk
24%
Hip Fracture
19%
Hospital Practice
15%
Low Molecular Weight Heparin
42%
Lupus Anticoagulant
16%
Lymphoma Patients
22%
Myeloproliferative Neoplasms
26%
Non-Hodgkin Lymphoma
81%
Oral Anticoagulant Therapy
16%
Oral Anticoagulants
15%
Oral Etoposide
15%
Patients with Cancer
26%
Peripheral Blood
16%
Philadelphia Chromosome-negative
52%
Platelet Aggregation
26%
Platelet Count
17%
Pregnant Women
19%
Primary Prophylaxis
16%
Prognostic Factors
26%
Recurrent Venous Thromboembolism
15%
Rituximab
16%
Thromboembolism
15%
Thrombophilia
39%
Thrombosis
30%
Thrombotic Complications
19%
Thrombotic Thrombocytopenic Purpura
26%
Venous Thromboembolism
33%
Working Diagnosis
17%
Medicine and Dentistry
Abscess
13%
Anticoagulation
16%
Antithrombotic
19%
Arsphenamine
13%
Arteriosclerosis Obliterans
13%
Atypical Hemolytic Uremic Syndrome
13%
Autoantibodies
15%
B-Cell Chronic Lymphocytic Leukemia
17%
Bleeding
15%
Blood Analysis
13%
Blood Clotting Factor
19%
Complement Factor H
13%
Danaparoid
13%
Direct Oral Anticoagulant
16%
Diseases
27%
Doxorubicin
15%
Eculizumab
13%
Essential Thrombocythaemia
16%
Etoposide
15%
Factor VII
19%
Fresh Frozen Plasma
19%
Glycoprotein
17%
Hemostat
21%
Hip Fracture
19%
Hodgkin's Lymphoma
13%
Immunoglobulin M
15%
Intrauterine Growth Retardation
14%
Low Molecular Weight Heparin
37%
Low Platelet Count
13%
Malignant Neoplasm
20%
Multiple Myeloma
13%
Non-Hodgkin Lymphoma
78%
Partial Thromboplastin Time
13%
Patient with Non-Hodgkins Lymphoma
45%
Platelet
27%
Pleura Effusion
13%
Rare Disease
13%
Reserpine
13%
Rituximab
19%
Side Effect
13%
Skin Necrosis
13%
Thrombocyte Aggregation
26%
Thrombocytosis
13%
Thromboembolism
27%
Thrombophilia
42%
Thrombosis
44%
Thrombotic Thrombocytopenic Purpura
42%
Tumor Antigen
13%
Venae cavae
13%
Venous Thromboembolism
36%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
14%
Alopecia
13%
Anticoagulant Agent
47%
Anticoagulation Therapy
13%
Antiphospholipid Antibody
26%
Blood Clotting Disorder
13%
Blood Clotting Factor 11
13%
Blood Clotting Factor 7
13%
Bloodstream Infection
13%
Bone Marrow Toxicity
13%
Campylobacter Jejuni
13%
Cellulitis
13%
Chemotherapy
32%
Chronic Lymphatic Leukemia
13%
Danaparoid
13%
Diseases
24%
Doxorubicin
13%
Etoposide
15%
First-Line Chemotherapy
13%
Fresh Frozen Plasma
13%
Hip Fracture
13%
Hodgkin Disease
21%
Hypothermia
13%
Immunoglobulin M
13%
Infection
29%
Intrauterine Growth Retardation
14%
Low Molecular Weight Heparin
26%
Lupus Anticoagulant
13%
Myeloproliferative Disorder
13%
Nonhodgkin Lymphoma
100%
Peripheral Occlusive Artery Disease
13%
Pleura Effusion
13%
Polycythemia vera
9%
Prevalence
11%
Protein C
13%
Protein S
13%
Rare Disease
13%
Recurrent Disease
9%
Remission
31%
Rituximab
13%
Side Effect
13%
Skin Necrosis
13%
Thrombocythemia
26%
Thromboembolism
25%
Thrombophilia
16%
Thrombosis
14%
Thrombotic Thrombocytopenic Purpura
26%
Tumor Antigen
13%
Venous Thromboembolism
16%
Warfarin
12%
